Innovative Cell Therapy, Omisirge, Receives FDA Approval to Reduce Infection Risk in Blood Cancer Treatments
The FDA has approved Omisirge (omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to speed up the recovery of neutrophils and reduce infection risk. Omisirge is intended for use in adults and pediatric patients aged 12 and older with blood cancers who are undergoing umbilical cord blood transplantation after a myeloablative conditioning regimen. Blood […]
Boosting Stem Cell Harvest: A Promising Combo Therapy Revolutionizes Transplant Success
A recent study published in the European Pharmaceutical Review has revealed that a combination therapy can significantly improve the collection of stem cells from donors. The therapy utilizes Plerixafor, a CXCR4 antagonist, in conjunction with granulocyte-colony stimulating factor (G-CSF), which helps mobilize stem cells from bone marrow to peripheral blood. The study found that this […]
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022. Ronald Martell, Chief Executive Officer, Jeet Mahal, Chief Operating & […]
ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients
MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today the publication of a scientific article entitled “UM171 expansion of cord blood improves donor availability and HLA […]